A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
EM
Encore MedicalEncore Medical develops transcatheter septal occlusion devices to repair structural heart defects like patent foramen ovale (PFO).
2 Pulse stories
Total RaisedNot disclosed
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2017
Cambridge, Massachusetts
HQ
Eagan, Minnesota
Public (APMD)
Status
Public (EMI)
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Encore Medical investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Encore Medical.